Submission to U.S. FDA
TORONTO, Jan. 25, 2021 /PRNewswire/ - SQI Diagnostics Inc.(the Company or SQI ) ( (TSXV: SQD); (OTCQB: SQIDF), a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced that patient enrollment began for the Company s clinical study for its direct-to-consumer COVID-19 HOME Antibody Test with the data to be used to support its EUA regulatory submission to the U.S. FDA.
The clinical study is being conducted in the United States and will analyze blood samples from both COVID-19 positive and negative subjects to meet FDA EUA guidelines. Blood samples are taken by the subjects at home and shipped and tested on SQI s automated sqidlite
SQI Diagnostics Announces $4 Million Funding via Warrant Exercise by Insiders
News provided by
Share this article
TORONTO, Dec. 30, 2020 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced that 19,074,997 common share purchase warrants of the Company (the Warrants ) have been exercised by certain insiders, who are control persons of the Company, for aggregate gross proceeds of approximately $4 million. SQI intends to use the proceeds from the $4 million funding to facilitate the clinical development, regulatory submission and commercialization of its direct-to-consumer COVID-19 HOME Antibody Test and both its RALI-dx